Roivant Sciences Ltd.
NASDAQ:ROIV
11.76 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 124.795 | 61.28 | 55.286 | 23.795 | 67.689 | 2.324 |
| Cost of Revenue
| 15.56 | 13.128 | 8.966 | 2.057 | 1.131 | 0.606 |
| Gross Profit
| 109.235 | 48.152 | 46.32 | 21.738 | 66.558 | 1.718 |
| Gross Profit Ratio
| 0.875 | 0.786 | 0.838 | 0.914 | 0.983 | 0.739 |
| Reseach & Development Expenses
| 501.736 | 525.215 | 483.035 | 236.626 | 263.217 | 512.994 |
| General & Administrative Expenses
| 0 | 600.506 | 775.033 | 259.878 | 335.766 | 237.214 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 687.443 | 600.506 | 775.033 | 259.878 | 335.766 | 237.214 |
| Other Expenses
| -85.032 | -62.193 | -0.081 | -33.405 | 0 | 0 |
| Operating Expenses
| 1,189.179 | 1,125.721 | 1,258.068 | 496.504 | 598.983 | 750.208 |
| Operating Income
| 4,242.016 | -1,077.569 | -1,211.748 | -1,070.898 | -532.425 | -748.49 |
| Operating Income Ratio
| 33.992 | -17.584 | -21.918 | -45.005 | -7.866 | -322.07 |
| Total Other Income Expenses Net
| 5,221.727 | -147.265 | 288.001 | 172.351 | -28.561 | -58.692 |
| Income Before Tax
| 4,253.43 | -1,224.834 | -923.747 | -898.547 | -560.986 | -807.182 |
| Income Before Tax Ratio
| 34.083 | -19.988 | -16.709 | -37.762 | -8.288 | -347.324 |
| Income Tax Expense
| 22.224 | 5.19 | 0.369 | 1.686 | 7.124 | 2.624 |
| Net Income
| 4,348.926 | -1,230.024 | -924.116 | -900.233 | 1,200.509 | -1,041.969 |
| Net Income Ratio
| 34.849 | -20.072 | -16.715 | -37.833 | 17.736 | -448.352 |
| EPS
| 5.55 | -1.73 | -1.38 | -4.04 | 5.21 | -4.84 |
| EPS Diluted
| 5.23 | -1.73 | -1.38 | -4.04 | 5.21 | -4.84 |
| EBITDA
| -996.515 | -1,107.578 | -1,499.83 | -510.503 | 83.855 | 138.126 |
| EBITDA Ratio
| -7.985 | -18.074 | -27.129 | -21.454 | 1.239 | 59.435 |